Actavia Life Sciences, Inc.
RASP
$0.004
-$0.0285-87.69%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -93.87% | 1,148.49% | 1,282.07% | 1,655.16% | 2,118.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -91.87% | 897.72% | 1,003.75% | 1,367.01% | 1,793.14% |
| Operating Income | 91.87% | -897.72% | -1,003.75% | -1,367.01% | -1,793.14% |
| Income Before Tax | 91.84% | -690.51% | -547.12% | -372.13% | -1,091.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 91.84% | -690.51% | -547.12% | -372.13% | -1,091.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 91.84% | -690.51% | -547.12% | -372.13% | -1,091.42% |
| EBIT | 91.87% | -897.72% | -1,003.75% | -1,367.01% | -1,793.14% |
| EBITDA | -- | -- | -- | 89.25% | 29.21% |
| EPS Basic | 96.21% | -289.47% | -56.86% | 12.77% | -116.39% |
| Normalized Basic EPS | 96.39% | 23.33% | 37.50% | 51.85% | 4.60% |
| EPS Diluted | 85.90% | -33.82% | 3.00% | 10.92% | -81.40% |
| Normalized Diluted EPS | 96.39% | 2.13% | 25.37% | 45.26% | -12.16% |
| Average Basic Shares Outstanding | 186.67% | 421.29% | 418.41% | 415.47% | 290.52% |
| Average Diluted Shares Outstanding | 186.67% | 341.16% | 322.54% | 295.63% | 185.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
